DNA

#3010
Ginkgo Bioworks Holdings, Inc.
7.7250 USD
+16.34%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
7.5600
7.7400
Rango anual
5.3700
9.7200
Cambio diario
+16.34%
Variación mensual
+10.36%
Variación en los últimos 6 meses
-13.01%
Cambio anual
-13.01%
Cierres anteriores
6.6400
Abrir
7.5600
Bid
Ask
Mínimo
7.5600
High
7.7400
Volumen
495
Ver el calendario completo

Financials

Visión general Informes Estadísticas
Trimestre Año
  • Market Capitalization 455.1906 M
  • Employee 485
  • Founded 2008
  • CEO Jason Kelly
  • Website www.ginkgobioworks.com
  • Headquarter Delaware, United States
  • FIGI BBG00YPS1KY3
  • Industry Technology
Ingresos totales
Beneficio neto
Beneficio básico por acción
Deuda total
Flujo de caja libre
Efectivo y equivalentes
Ratio precio/beneficio
-1.47
Relación precio/flujo de caja
2.71

Ginkgo Bioworks Holdings Inc Class A

Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It raised $290 million in September and $350 million in October of that year. Ginkgo Bioworks went public on the New York Stock Exchange via a SPAC merger on September 17, 2021.

Noticias